Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
CNMD · NYSE · United States · Electromedical & Electrotherapeutic Apparatus
In shortCONMED Corp is profitable, generates cash and carries moderate debt, with revenue growing (+5.2% last year).
Financial health
Solid
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 7.5% | 42/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 3.4% | 34/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 4.7% | 24/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 3.6% | 24/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 2.14× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.81× | 66/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | 6.63× | 0/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | 3.30× | 17/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 2.97 | 48/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 11.0% | 64/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 3.21× | 100/100 |
| Years with positive free cash flow (last 5) | 5 of 5 | 100/100 |
Weight in the score: 20%
| Profitable years (last 5) | 4 of 5 | 80/100 |
|---|---|---|
| Years of revenue decline (last 5) | 0 of 5 | 100/100 |
| Revenue growth volatility | 7.5% | 83/100 |
| Operating margin volatility | 3.4% | 78/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 9.6% | 70/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 1,011 | 1,045 | 1,245 | 1,307 | 1,375 |
| Cost of revenue | 443 | 474 | 568 | 574 | 624 |
| Gross profit | 568 | 571 | 676 | 733 | 750 |
| Research & development | 44 | 47 | 53 | 54 | 56 |
| Selling, general & admin | 415 | 454 | 503 | 478 | 592 |
| Operating income | 110 | 70 | 121 | 200 | 103 |
| Interest expense | 35 | 29 | 40 | 37 | 31 |
| Pre-tax income | 73 | (71) | 81 | 163 | 71 |
| Income tax | 11 | 9.7 | 16 | 31 | 24 |
| Net income | 63 | (81) | 64 | 132 | 47 |
| Diluted EPS | $1.94 | −$2.68 | $2.04 | $4.25 | $1.51 |
| Diluted shares (millions) | 32 | 30 | 32 | 31 | 31 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 8 reported quarters (10-Q and 10-K filings), in USD millions. The fourth quarter is derived from the annual report.
The last 8 quarters of CONMED Corp are included in the Investor plan. Try free for 7 days →
2.97 Safe zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
6/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Jul 29, 2026